In unresectable stage III NSCLC, the combination tested in the COAST phase II trial enhanced the anti-tumor response and improved PFS independently of PD-L1 status, leading to a phase III study initiation in this indication12,19. This evidence concerns the gene CD274 and non-small cell lung carcinoma.